Loncastuximab for relapsed or treatment-resistant marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests loncastuximab tesirine, a medicine that targets lymphoma cells, in people with marginal zone lymphoma that came back or did not respond to prior treatment. It aims to see how well the treatment can control the disease and shrink lymphoma in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have confirmed marginal zone lymphoma (in tissue biopsy), including nodal, splenic, or extranodal types.
- Your lymphoma has come back or did not improve after at least one prior whole-body treatment that included an anti-CD20 antibody (for example, rituximab).
- You have measurable disease on recent scans (CT/MRI within 6 weeks), OR you may qualify with special situations like certain splenic, skin, gastric, or eye (conjunctival) involvement.
- You can provide a recent biopsy of tissue (or agree to a new biopsy if needed).
- Your overall body strength and organ tests are good enough for treatment (blood counts, kidney, and liver), and you can avoid pregnancy/fathering during the required time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.